Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer.

Autor: Puisset F; Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.; CRCT, Cancer Research Center of Toulouse, Inserm U1037, Université Paul Sabatier, 31037 Toulouse, France., Mseddi M; Department of Pharmacokinetics and Pharmacochemistry, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, CARPEM, 75014 Paris, France., Mourey L; Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France., Pouessel D; Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France., Blanchet B; Department of Pharmacokinetics and Pharmacochemistry, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, CARPEM, 75014 Paris, France.; UMR8038 CNRS, U1268 INSERM, Faculté de Pharmacie, Université Paris Cité, PRES Sorbonne Paris Cité, CARPEM, 75006 Paris, France., Chatelut E; Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.; CRCT, Cancer Research Center of Toulouse, Inserm U1037, Université Paul Sabatier, 31037 Toulouse, France., Chevreau C; Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2023 Jan 03; Vol. 15 (1). Date of Electronic Publication: 2023 Jan 03.
DOI: 10.3390/cancers15010313
Abstrakt: Seven tyrosine kinase inhibitor compounds with anti-angiogenic properties remain key drugs to treat advanced renal cell carcinoma. There is a strong rationale to develop therapeutic drug monitoring for these drugs. General considerations of such monitoring of the several groups of anticancer drugs are given, with a focus on oral therapy. Pharmacokinetics and the factors of inter- and intraindividual variabilities of these tyrosine kinase inhibitors are described together with an exhaustive presentation of their pharmacokinetic/pharmacodynamic relationships. The latter was observed in studies where every patient was treated with the same dose, and the results of several prospective studies based on dose individualization support the practice of increasing individual dosage in case of low observed plasma drug concentrations. Finally, the benefits and limits of therapeutic drug monitoring as a routine practice are discussed.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje